The Administration and Clinical Trial Coordination Core A will serve as the central organizational hub of the Program. This Core will have 5 main functions: 1) To coordinate the administrative and fiscal management of the Program Project; 2) To provide research coordination and review through meetings of internal program members and external consultants; 3) To provide support for all of the clinical trials by providing consistency in IRB interactions, severe adverse event reporting, clinical grading of graft vs host disease and regulatory expertise; 4) To coordinate follow-up of patients who have undergone transplantation on clinical trials of this PPG; 5) To ensure access of both genders and all minorities to clinical trials. The Core will provide oversight and fiscal management to the Project and coordinate these efforts through dedicated personnel with expertise in these defined areas. Since many of the clinical trials require FDA oversight through INDs central coordination of this effort through organization of the INDs, communication with the FDA and reporting of outcomes to institutional and external regulatory bodies will be a critical role for the Core. Centralizing this effort will provide expertise and consistency in these efforts. The Core will organize and facilitate a panel of external consultants who will visit the Program yearly and provide critique and guidance. A monthly Program Project meeting will also be organized by the Core. The Core leader will liaison with Divisional, Departmental and Cancer Center personnel to enhance interactions and facilitate discoveries. All of the Projects and Cores will utilize Core A functions.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
United States
Zip Code
Chen, Yi-Bin; Efebera, Yvonne A; Johnston, Laura et al. (2017) Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant 23:625-634
Spinner, Michael A; Fernández-Viña, Marcelo; Creary, Lisa E et al. (2017) HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Adv 1:1347-1357
Costa, Helio A; Neal, Joel W; Bustamante, Carlos D et al. (2017) Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer. Mol Diagn Ther 21:431-436
Xu, Liwen; You, Xiaoqing; Zheng, PingPing et al. (2017) Methodologic Considerations in the Application of Next-Generation Sequencing of Human TRB Repertoires for Clinical Use. J Mol Diagn 19:72-83
Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125
Paul, Jed; Sahaf, Bita; Perloff, Spenser et al. (2016) High-throughput allogeneic antibody detection using protein microarrays. J Immunol Methods 432:57-64
Ozawa, Michael G; Bhaduri, Aparna; Chisholm, Karen M et al. (2016) A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma. Mod Pathol 29:1212-20
Kelley, Todd W; Arber, Daniel A; Gibson, Christine et al. (2016) Template for Reporting Results of Biomarker Testing of Specimens From Patients With Myeloproliferative Neoplasms. Arch Pathol Lab Med 140:675-7
Sen, Nandini; Arvin, Ann M (2016) Dissecting the Molecular Mechanisms of the Tropism of Varicella-Zoster Virus for Human T Cells. J Virol 90:3284-7
Khodadoust, M S; Luo, B; Medeiros, B C et al. (2016) Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia 30:947-50

Showing the most recent 10 out of 304 publications